albuterol / budesonide vs ciclesonide (Alvesco)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Glucocorticoid receptor · full Asthma pipeline

albuterol / budesonide · Airsupra

Marketed by AstraZeneca

Approved in Asthmacombination (SABA + ICS)
Reliable signal

NCT03769090 · Phase 3 · completed

Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).

Next expected readout: February 2027 · NCT06422689 (registry estimate)

Reported efficacy

Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212 (met)

Result source: NCT05505734

ciclesonide (Alvesco)

Marketed by Azurity Pharmaceuticals and partners

Approved in Asthmasmall molecule (corticosteroid)
Reliable signal

NCT00163397 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial comparing ciclesonide to budesonide, using lung function (FEV1) as the primary endpoint -- a regulator-accepted objective measure for asthma. The trial was designed as a non-inferiority comparison, and the prespecified margin test succeeded, meaning ciclesonide performed comparably to the active comparator on its primary measure.

Result from the sponsor's published study results summary; no peer-reviewed publication or posted CT.gov results were found.

Reported efficacy

Change from baseline to Week 16 in FEV1: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone (met)

Result source: NCT00174720

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointalbuterol /​ budesonideciclesonide (Alvesco)
Severe exacerbations, annualised rate0.5 vs 0.6vs AS MDI80/180 μg · n 1054NCT03769090
2 other results
  • 0.1 vs 0.3 160/180 μg · n 1209 · Phase 3 · secondary NCT05505734
  • 0.1 vs 0.3 160/180 μg · n 1180 · Phase 3 · secondary NCT05505734
—Not posted · NCT00174720
Trough FEV1, change0.1 vs 0.0+0.1 vs placebo160/180 μg · wk 12 · n 197NCT03847896
3 other results
  • 0.1 vs 0.0 80/180 μg · wk 12 · n 198 · Phase 3 · primary NCT03847896
  • 0.1 vs 0.0 160/180 μg · wk 1 · n 197 · Phase 3 · secondary NCT03847896
  • 0.1 vs 0.0 80/180 μg · wk 1 · n 198 · Phase 3 · secondary NCT03847896
—Not posted · NCT00174720
ACQ-5, change—Not posted · NCT06502366—Not posted · NCT00174720
OCS dose reduction—Not posted · NCT06502366—Not posted · NCT00174720

Severe exacerbations, annualised rate

albuterol /​ budesonide
0.5 vs 0.6vs AS MDI80/180 μg · n 1054NCT03769090
2 other results
  • 0.1 vs 0.3 160/180 μg · n 1209 · Phase 3 · secondary NCT05505734
  • 0.1 vs 0.3 160/180 μg · n 1180 · Phase 3 · secondary NCT05505734
ciclesonide (Alvesco)
—Not posted · NCT00174720

Trough FEV1, change

albuterol /​ budesonide
0.1 vs 0.0+0.1 vs placebo160/180 μg · wk 12 · n 197NCT03847896
3 other results
  • 0.1 vs 0.0 80/180 μg · wk 12 · n 198 · Phase 3 · primary NCT03847896
  • 0.1 vs 0.0 160/180 μg · wk 1 · n 197 · Phase 3 · secondary NCT03847896
  • 0.1 vs 0.0 80/180 μg · wk 1 · n 198 · Phase 3 · secondary NCT03847896
ciclesonide (Alvesco)
—Not posted · NCT00174720

ACQ-5, change

albuterol /​ budesonide
—Not posted · NCT06502366
ciclesonide (Alvesco)
—Not posted · NCT00174720

OCS dose reduction

albuterol /​ budesonide
—Not posted · NCT06502366
ciclesonide (Alvesco)
—Not posted · NCT00174720
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. albuterol / budesonide: 4 of 4 rows · ciclesonide (Alvesco): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricalbuterol /​ budesonideciclesonide (Alvesco)
Dropout rate
9.9%160/180 μga
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
11.7%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
28.2%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
3.6%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
7.8%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
—160/180
NCT06245551 · Phase 3
—
NCT05555290 · Phase 3 · registry result, not featured evidence
—
NCT04234464 · Phase 3 · registry result, not featured evidence
—160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
—b
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
11.8%
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy
Discontinued due to AEs
0.7%160/180 μga
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
0.7%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
0.5%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
1%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
0.5%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
—160/180
NCT06245551 · Phase 3
—
NCT05555290 · Phase 3 · registry result, not featured evidence
—
NCT04234464 · Phase 3 · registry result, not featured evidence
—160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
—b
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
5.1%
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy
Serious AEs
5.2%160/180 μga
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
3.8%80/180 μg
NCT03769090 · Phase 3 · Asthma · phase 3
3.1%160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
1%160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
2%80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
0%160/180
NCT06245551 · Phase 3
0%
NCT05555290 · Phase 3 · registry result, not featured evidence
0%
NCT04234464 · Phase 3 · registry result, not featured evidence
0%160/180 μg
NCT04848662 · Phase 1 · registry result, not featured evidence
0%b
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
0.8%
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy
Most frequent reported AEs
160/180 μga
nasopharyngitis 7.5%
headache 4.3%
covid-19 3.3%
NCT03769090 · Phase 3 · Asthma · phase 3
show 8 more results
80/180 μg
nasopharyngitis 5.8%
headache 4.7%
covid-19 4.5%
NCT03769090 · Phase 3 · Asthma · phase 3
160/180 μg
upper respiratory tract infection 5.4%
covid-19 5.1%
nasopharyngitis 3.7%
NCT05505734 · Phase 3 · Asthma · phase 3
160/180 μg
nasopharyngitis 7.6% (placebo 5.5%)
headache 5.1% (placebo 7%)
dysphonia 2% (placebo 0%)
NCT03847896 · Phase 3 · Asthma · phase 3
80/180 μg
nasopharyngitis 6.4% (placebo 5.5%)
headache 4.9% (placebo 7%)
upper respiratory tract infection 1.5% (placebo 1%)
NCT03847896 · Phase 3 · Asthma · phase 3
160/180
bronchial irritation 1.6% (placebo 0%)
diarrhoea 0% (placebo 1.6%)
headache 0% (placebo 1.6%)
NCT06245551 · Phase 3
anxiety 1%
cough 1%
covid-19 1%
NCT05555290 · Phase 3 · registry result, not featured evidence
anxiety 0% (placebo 1.7%)
dyspnoea 0% (placebo 1.7%)
NCT04234464 · Phase 3 · registry result, not featured evidence
160/180 μg
miliaria 0%
NCT04848662 · Phase 1 · registry result, not featured evidence
b
headaches/migraine 23.8% (placebo 22.7%)
respiratory infections 19% (placebo 18.2%)
bilateral otitis media 4.8% (placebo 0%)
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4

Notes

  1. aPopulation comparability has not been reviewed for 4 of these studies.
  2. bPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

albuterol / budesonide

Severe Exacerbation 22.9% (n=1054) vs 26.2% (n=1014) AS MDI80/180 μg
event rate · % of participants
NCT03769090 · Phase 3 · Asthma · phase 3 · converted to % from 241 Participants as posted
Severe Exacerbation Rate Annualized 0.49 vs 0.59 AS MDI per year80/180 μg
event rate · per year
NCT03769090 · Phase 3 · Asthma · phase 3
show 2 more results
0.15 vs 0.32 PT007 per year160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
0.15 vs 0.33 PT007 per year160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
ACQ-5 64.7% (n=1052) vs 62.1% (n=1014) AS MDI @ 24wk80/180 μg
responder rate · % of participants
NCT03769090 · Phase 3 · Asthma · phase 3 · converted to % from 681 Participants as posted
Time to First Severe Exacerbation 5.1% (n=1209) vs 9.1% (n=1212) PT007160/180 μg
event count · % of participants
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 62 Participants as posted
show 3 more results
5.3% (n=1209) vs 9.4% (n=1212) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 64 Participants as posted
6% (n=1180) vs 10.7% (n=1173) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 71 Participants as posted
6.2% (n=1180) vs 11.2% (n=1173) PT007*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to % from 73 Participants as posted
Total Systemic Glucocorticoid Exposure mg Per 23.2 vs 61.9 PT007 per year160/180 μg
absolute value · per year
NCT05505734 · Phase 3 · Asthma · phase 3
show 1 more result
23 vs 63 PT007 per year160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3
Total Systemic Glucocorticoid Duration 0.01 vs 0.03 PT007 months160/180 μg
absolute value · months
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to months from 0.4 days as posted
show 1 more result
0.01 vs 0.03 PT007 months*160/180 μg
NCT05505734 · Phase 3 · Asthma · phase 3 · converted to months from 0.4 days as posted
FEV1 AUC0-6 0.259 vs 0.097 placebo L @ 12wk160/180 μg
absolute change · L
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to L from 258.6 mL as posted
show 1 more result
0.242 vs 0.097 placebo L @ 12wk*80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to L from 242.2 mL as posted
FEV1 Trough 0.136 vs 0.036 placebo L @ 12wk160/180 μg
absolute change · L
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to L from 135.5 mL as posted
show 3 more results
0.124 vs 0.036 placebo L @ 12wk*80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to L from 123.5 mL as posted
0.107 vs 0.041 placebo L @ 1wk*160/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to L from 107.2 mL as posted
0.072 vs 0.041 placebo L @ 1wk*80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to L from 72 mL as posted
Time to FEV1 15 Increase 7.5 vs 14 placebo minutes @ 0wk160/180 μg
absolute value · minutes
NCT03847896 · Phase 3 · Asthma · phase 3
show 1 more result
7 vs 14 placebo minutes @ 0wk80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
Duration of FEV1 15 Increase 185.5 vs 229.5 placebo minutes @ 0wk160/180 μg
absolute value · minutes
NCT03847896 · Phase 3 · Asthma · phase 3
show 1 more result
174 vs 229.5 placebo minutes @ 0wk80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3
ACQ-7 66.5% (n=161) vs 55.3% (n=159) placebo @ 12wk160/180 μg
responder rate · % of participants
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to % from 107 Participants as posted
show 1 more result
65.5% (n=165) vs 55.3% (n=159) placebo @ 12wk*80/180 μg
NCT03847896 · Phase 3 · Asthma · phase 3 · converted to % from 108 Participants as posted
FEV1 Max Fall 6.95% (n=64) vs 24.46% (n=64) placebo160/180
absolute value · percentage points
All subjects
NCT06245551 · Phase 3

+ 13 further endpoints in the CSV export.

ciclesonide (Alvesco)

Lower Leg Growth Velocity MM Wk 0.23 vs 0.33 Beconase and QVAR mm @ 52wk
absolute value · mm
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
0.23 vs 0.51 placebo mm @ 52wk
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
ACQ -0.76 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · ciclesonide (Alvesco)'s landscape